BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel. Show more

Location: 22 Einstein Street, Ness Ziona, 7414003, Israel | Website: https://www.biomx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

3.16M

52 Wk Range

$1.50 - $22.06

Previous Close

$2.07

Open

$2.04

Volume

30,166

Day Range

$1.96 - $2.09

Enterprise Value

21.44M

Cash

6.923M

Avg Qtr Burn

-7.073M

Insider Ownership

17.22%

Institutional Own.

32.01%

Qtr Updated

09/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BX011 Details Staphylococcus aureus (S. aureus) in diabetic foot infections (DFI)	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BX004 Details Cystic Fibrosis, P. aeruginosa lung infections	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.